Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug tirzepatide put to the test in paraguay clinic

NCT ID NCT07492563

Disease control Sponsor: LABORATORIOS INDUFAR Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test the safety and effectiveness of tirzepatide, a once-weekly injection, in 300 adults with obesity or overweight plus related health problems. Participants will receive increasing doses over 12 months while doctors track side effects, weight loss, and improvements in blood sugar and blood pressure. The goal is to see how well the drug works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If successful, this study could confirm tirzepatide as a safe and effective option for long-term weight and diabetes management in real-world settings.
What could go wrong
This is an early-phase observational study, not a large confirmatory trial. Side effects like nausea or more serious events are possible, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who attend the Endocrinology Unit of Hospital de Clínicas, Universidad Nacional de Asunción, Paraguay

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * BMI ≥27 kg/m² with weight-related comorbidities OR BMI ≥35 kg/m² * Clinical indication for tirzepatide per treating physician * Paraguayan citizenship or permanent residence * Residence in Asunción or Metropolitan Area or possibility to assist to regular visits * Ability to attend visits for 12 months * Ability to provide written informed consent Exclusion Criteria: * Type 1 diabetes or secondary diabetes * Known hypersensitivity to tirzepatide * Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome * Acute pancreatitis in last 12 months or chronic pancreatitis * Severe gastrointestinal disease * Bariatric surgery in last 12 months * Pregnancy or breastfeeding * Severe renal impairment (eGFR \<30 mL/min/1.73m²) * Severe hepatic impairment (Child-Pugh B or C) * Unstable cardiovascular disease * Active cancer (except non-melanoma skin cancer completely resected) * Current use of other GLP-1 receptor agonists * Participation in another interventional trial within 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight with comorbidities Type 2 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Endocrinology Unit, UNA, Py

    Asunción, Paraguay

More trials for these conditions

Other studies related to the condition(s) this trial covers.